Weijia Fang, Md
Clinical trials sponsored by Weijia Fang, Md, explained in plain language.
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called Anti-CEA CAR-T for people with advanced solid tumors (like colorectal or stomach cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target a protein called CEA fou…
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New CAR-T therapy targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…
Phase: PHASE1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC